Subscribe to Newsletter

Clinical Trials

Discovery & Development Business Practice

Detecting agglomerates within pharmaceutical formulations

Particle agglomeration can compromise the clinical efficacy of pharmaceutical products and must therefore be closely controlled. This article provides practical guidance on using automated imaging for efficient agglomerate detection.

Manufacture Business Practice

Using GPC/SEC for excipient characterization

OMNISEC measures the Critical Quality Attributes of polymeric pharmaceutical excipients with unrivalled sensitivity supporting their efficient use to formulate safe and effective pharmaceutical products.

Discovery & Development Business Practice

Trials and Tribulations

| Angus Dalgleish

Angus Dalgleish tells us about his experience with EU regulation – and why he thinks Britain should leave the EU.

Discovery & Development Small Molecules

Doyenne of Discovery

| Mike Schäfers

Sitting Down With... Ann Hayes, Owner, The Ann Hayes Consultancy, Stevenage, UK.

Discovery & Development Clinical Trials

More Trial, Less Error

| Sponsored by Catalent

The pressure for increased efficiency pervades the pharma industry, including the clinical trials sector, where traditional supply models can lead to overstocking, waste and higher costs. Is there a more effective supply strategy?

Business & Regulation Clinical Trials

Back to Biologics

| Christian Schneider

Sitting Down With... Christian Schneider, Director of the National Institute for Biological Standards and Control (NIBSC), UK.

Discovery & Development Business Practice

The Numbers Game

Statisticians are vital in the pharma industry, but rarely do they receive public fanfare for their work. The Award for Statistical Excellence in the Pharmaceutical Industry aims to change the status quo.

Discovery & Development Business Practice

Accelerate liquid formulation development for protein biopharmaceuticals

The work presented here illustrates how Differential Scanning Calorimetry (DSC) is used in the early stages of protein characterization to rapidly provide critical data about protein stability that can be used as a guide to support and accelerate liquid formulation.

Discovery & Development Clinical Trials

Clinical Trial Tragedy

A clinical trial of an FAAH inhibitor in France goes terribly wrong, but whether the compound or manufacturing are to blame remains to be seen

Discovery & Development Clinical Trials

A Brave New Year

| Stephanie Vine

How do we move on from a sombre start to 2016?

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register